ARCA biopharma, Inc (ABIO) is a leading biotechnology business based in the US. ARCA biopharma is listed on the NASDAQ and employs 13 staff. All prices are listed in US Dollars.
|52-week range||$2.21 - $10.25|
|50-day moving average||$4.2782|
|200-day moving average||$4.9181|
|Wall St. target price||$7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-6.667|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Gross profit TTM||$0|
|Return on assets TTM||-11.94%|
|Return on equity TTM||-19.71%|
|Market capitalisation||$43.4 million|
TTM: trailing 12 months
There are currently 126,649 ARCA biopharma shares held short by investors – that's known as ARCA biopharma's "short interest". This figure is 208.2% up from 41,092 last month.
There are a few different ways that this level of interest in shorting ARCA biopharma shares can be evaluated.
ARCA biopharma's "short interest ratio" (SIR) is the quantity of ARCA biopharma shares currently shorted divided by the average quantity of ARCA biopharma shares traded daily (recently around 527704.16666667). ARCA biopharma's SIR currently stands at 0.24. In other words for every 100,000 ARCA biopharma shares traded daily on the market, roughly 240 shares are currently held short.
However ARCA biopharma's short interest can also be evaluated against the total number of ARCA biopharma shares, or, against the total number of tradable ARCA biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ARCA biopharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ARCA biopharma shares in existence, roughly 10 shares are currently held short) or 0.0136% of the tradable shares (for every 100,000 tradable ARCA biopharma shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ARCA biopharma.
Find out more about how you can short ARCA biopharma stock.
We're not expecting ARCA biopharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
ARCA biopharma's shares were split on a 1:18 basis on 4 April 2019. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your ARCA biopharma shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for ARCA biopharma shares which in turn could have impacted ARCA biopharma's share price.
Over the last 12 months, ARCA biopharma's shares have ranged in value from as little as $2.21 up to $10.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ARCA biopharma's is 2.803. This would suggest that ARCA biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.